GlassScriptPhysician profile
Brian C Carty
NPI 1467434886
$1,768.78
in general payments reported to CMS, 2019-2025
19 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $385 · 2022: $51.63 · 2023: $133 · 2024: $40.61 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.54 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $441.21 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $160.72 | 2019-2020 | |
| Abbvie INC. | $105.70 | 2019-2023 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $94.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.60 | 2019 | |
| Hologic Sales and Service, LLC | $40.61 | 2024 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $38.86 | 2019 | |
| Boston Scientific Corporation | $36.95 | 2019 | |
| Astellas Pharma US INC | $31.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.69 | 2019 | |
| Duchesnay USA Incorporated | $24.37 | 2019 | |
| Aytu Biopharma, INC. | $24.07 | 2019 | |
| Gilead Sciences, INC. | $23.05 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.31 | 2020 | |
| Abbott Laboratories | $19.69 | 2020 | |
| Ironshore Pharmaceuticals INC. | $18.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Carty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.